Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer

World Journal of Urology

Volumn 29, Issue 5, 2011, Pages 689-694

  Fujisue, Yutaka ^a   Azuma, Haruhito ^a   Inamoto, Teruo ^a   Komura, Kazumasa ^a   Agarwal, Piyush K ^b   Masuda, Hiroshi ^a   Watsuji, Toshikazu ^c   Katsuoaka, Yoji ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b HENRY FORD HOSPITAL   (United States)

^c Hirakata City Hospital   (Japan)

Author keywords

HIFU; Hormonal therapy; Prostate cancer; PSA

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; AGED; ARTICLE; BLOOD; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 80053619527     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0628-1     Document Type: Article

References (18)

1. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11): 969-974.
2. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the rtog-astro phoenix consensus conference. Int J Radiat Oncol Biol Phys 65(4): 965-974. doi: 10. 1016/j. ijrobp. 2006. 04. 029.
3. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR (2003) National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95(13): 981-989.
4. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff JM, Deapen D, Stephenson RA, Legler J, Ferrans CE, Talcott JA, Litwin MS (1999) Prostate cancer practice patterns and quality of life: the prostate cancer outcomes study. J Natl Cancer Inst 91(20): 1719-1724.
5. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341(24): 1781-1788.
6. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K (2002) Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 90(6): 561-566.
7. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2): 154-164. doi: 10. 1056/NEJMoa041943.
8. Keating NL, O'Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1): 39-46. doi: 10. 1093/jnci/djp404.
9. Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE (2009) Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 55(1): 62-75. doi: 10. 1016/j. eururo. 2008. 10. 008.
10. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: Rtog 85-31. J Clin Oncol 27(1): 92-99. doi: 10. 1200/JCO. 2007. 12. 3752.
11. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A (2008) First analysis of the long-term results with transrectal hifu in patients with localised prostate cancer. Eur Urol 53(6): 1194-1201. doi: 10. 1016/j. eururo. 2007. 10. 062.
12. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A (2008) Psa nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (hifu) treatment of localised prostate cancer. Eur Urol 53(3): 547-553. doi: 10. 1016/j. eururo. 2007. 07. 010.
13. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A (2006) Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 97(1): 56-61. doi: 10. 1111/j. 1464-410X. 2006. 05864. x.
14. Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B (2006) Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 24(5): 585-590. doi: 10. 1007/s00345-006-0107-x.
15. Chaussy C, Thuroff S (2003) The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4(3): 248-252.
16. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A (2007) Control of prostate cancer by transrectal hifu in 227 patients. Eur Urol 51(2): 381-387. doi: 10. 1016/j. eururo. 2006. 04. 012.
17. Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M (2009) High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first uk series. Br J Cancer 101(1): 19-26. doi: 10. 1038/sj. bjc. 6605116.
18. Shoji S, Nakano M, Nagata Y, Usui Y, Terachi T, Uchida T (2010) Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: a prospective study. Int J Urol 17(8): 715-719. doi: 10. 1111/j. 1442-2042. 2010. 02568. x.